Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
作者信息
Nybakken G E, Canaani J, Roy D, Morrissette J D, Watt C D, Shah N P, Smith C C, Bagg A, Carroll M, Perl A E
机构信息
Department of Pathology, Kaiser Permanente Santa Clara, CA, USA.
Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Leukemia. 2016 Jun;30(6):1422-5. doi: 10.1038/leu.2015.320. Epub 2015 Nov 20.
Abstract
摘要
相似文献
1
Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
Leukemia. 2016 Jun;30(6):1422-5. doi: 10.1038/leu.2015.320. Epub 2015 Nov 20.
2
The role of quizartinib in the treatment of acute myeloid leukemia.
Expert Opin Investig Drugs. 2013 Dec;22(12):1659-69. doi: 10.1517/13543784.2013.842973. Epub 2013 Sep 26.
3
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
Future Oncol. 2014;10(9):1571-9. doi: 10.2217/fon.14.105.
4
Quizartinib in acute myeloid leukemia.
Clin Adv Hematol Oncol. 2013;11(9):586-8.
5
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Leukemia. 2013 Jun;27(6):1416-8. doi: 10.1038/leu.2013.14. Epub 2013 Jan 16.
6
Quizartinib, the next FLT3 inhibitor.
Clin Adv Hematol Oncol. 2023 May;21(5):240-243.
7
[Quizartinib associated to chemotherapy in newly diagnosed patients with FLT3-ITD positive acute myeloid leukemia].
Bull Cancer. 2024 Sep;111(9):793-794. doi: 10.1016/j.bulcan.2024.02.012. Epub 2024 Jun 13.
8
Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?
Transplant Cell Ther. 2021 Feb;27(2):99-100. doi: 10.1016/j.jtct.2021.01.002. Epub 2021 Jan 6.
9
Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment.
Leukemia. 2021 Feb;35(2):601-605. doi: 10.1038/s41375-020-0893-y. Epub 2020 Jun 8.
10
Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors.
Exp Hematol. 2024 Sep;137:104253. doi: 10.1016/j.exphem.2024.104253. Epub 2024 Jun 13.
引用本文的文献
1
Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3ANPM1FLT3-ITD in acute myeloid leukemia: real-world multicenter analysis in China.
Front Med. 2025 Feb;19(1):90-100. doi: 10.1007/s11684-024-1091-5. Epub 2024 Dec 7.
2
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.
J Hematol Oncol. 2024 Nov 13;17(1):111. doi: 10.1186/s13045-024-01617-7.
3
Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.
Int J Hematol. 2025 Jan;121(1):137-143. doi: 10.1007/s12185-024-03863-4. Epub 2024 Oct 26.
4
How I treat acute myeloid leukemia with differentiation therapy.
Blood. 2025 Mar 20;145(12):1251-1259. doi: 10.1182/blood.2024024008.
5
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Leukemia. 2024 Feb;38(2):291-301. doi: 10.1038/s41375-023-02131-4. Epub 2024 Jan 5.
6
Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.
Cell Genom. 2023 Oct 27;3(12):100426. doi: 10.1016/j.xgen.2023.100426. eCollection 2023 Dec 13.
7
Differentiation Syndrome in Acute Leukemia: APL and Beyond.
Cancers (Basel). 2023 Sep 28;15(19):4767. doi: 10.3390/cancers15194767.
8
Evaluation of hypereosinophilia in a case of -mutant acute myeloid leukemia treated with gilteritinib.
Cold Spring Harb Mol Case Stud. 2023 Jul 11;9(3). doi: 10.1101/mcs.a006279. Print 2023 Jun.
9
Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results.
Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023031. doi: 10.4084/MJHID.2023.031. eCollection 2023.
10
Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021.
本文引用的文献
1
DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
Clin Cancer Res. 2015 Apr 1;21(7):1614-20. doi: 10.1158/1078-0432.CCR-14-0327. Epub 2015 Jan 21.
2
Inhibition of c-Kit by tyrosine kinase inhibitors.
Haematologica. 2015 Mar;100(3):e77-9. doi: 10.3324/haematol.2014.117028. Epub 2014 Nov 25.
3
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12.
4
Genomic landscapes and clonality of de novo AML.
N Engl J Med. 2013 Oct 10;369(15):1473. doi: 10.1056/NEJMc1308782.
5
FLT3 inhibitor-induced neutrophilic dermatosis.
Blood. 2013 Jul 11;122(2):239-42. doi: 10.1182/blood-2013-01-478172. Epub 2013 May 17.
6
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
Blood. 2012 Nov 15;120(20):4205-14. doi: 10.1182/blood-2012-01-402545. Epub 2012 Sep 25.
7
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.
8
Dnmt3a is essential for hematopoietic stem cell differentiation.
Nat Genet. 2011 Dec 4;44(1):23-31. doi: 10.1038/ng.1009.
9
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Leukemia. 2009 Oct;23(10):1731-43. doi: 10.1038/leu.2009.124. Epub 2009 Jun 11.
10
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
Blood. 2007 Feb 15;109(4):1643-52. doi: 10.1182/blood-2006-05-023804. Epub 2006 Oct 17.
Zotero 插件